Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israel, Tel Aviv
David Sarid
38 years of experience
accreditations :
Clinic is certified :
Targeted therapy in Israel typically ranges from $9,500 to $19,500 depending on the protocol and cancer type. Patients save around 64% compared to the US, where this procedure costs $40,000 on average. Major medical hubs include Tel Aviv, Jerusalem, and Haifa. Costs usually include the medication, oncologist consultations, genomic testing, and administration in specialized oncology day-care units.
Bookimed Expert Insight: Israeli oncology centers offer significant value by providing access to early-phase clinical trials. For instance, Sourasky Medical Center (Ichilov) implements the PSIFAS National Genomic Medicine Initiative. Patients can find breast cancer packages starting around $2,050 including KADCYLA protocols. Choosing JCI-accredited clinics like Assuta or Hadassah ensures international safety standards while maintaining lower costs than US private care.
Why choose Israel for targeted therapy?
Access advanced Targeted therapy solutions in trusted clinics .
| Israel | Turkey | Austria | |
| Targeted therapy | from $9,500 | from $1,000 | from $12,000 |
| Lutetium-177 therapy | from $16,500 | from $10,000 | from $35,000 |
| Oncothermia | - | from $450 | - |
| Actinium-225 Therapy | - | from $22,955 | from $55,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Targeted therapy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Targeted therapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Targeted therapy journey.
Day 1: Arrival
Day 2: Pre-Operation Stage
Day 3: Targeted Therapy
Day 4: Post-Operation Stage
Week 1-2: Rehabilitation
Please note that each patient"s case is individual and can vary.
What patients like:
What patients don't like:
As the leading global medical tourism platform, we have a huge responsibility to our clients, both patients and medical centers, in Targeted therapy. All the information provided on Bookimed.com is grounded in research, foresight, and expertise and meets high interest related to the product and follows:
We form our listings of clinics and doctors with strict regulations of our smart automatic ranking system in Israel. The system is based on real Bookimed patient rates to provide the most objective and transparent information about clinics and medical services there.
Our experienced data scientist collects data daily, monitors, and optimizes the ranking system using machine learning and artificial intelligence to ensure that the ranking system is up-to-date and provides accurate results.
We collect the opinions of Bookimed clients only after getting medical experience with the clinic in Israel so everyone on the platform can trust the facility they choose for Targeted therapy. We strive to make the content on our platform as useful as possible and ensure the freedom to express critical opinions. Thus, we publish positive and negative reviews, aiming at being a source for informed decision-making for our future clients.
On Bookimed.com, you may find choice and convenience to find the best medical solutions from top medical services providers just in one place, and often at competitive prices in Israel. Making sure to deliver the freshest information, the clinic’s representatives update doctors’ CVs, clinics’ capacities, before-after pictures, prices, packages, and specials by themselves shortly. You may meet the clinic’s representative and check the date of updated content at every clinic’s page to make sure of its trustworthiness.
Our blog and supportive pieces are created by professional authors with at least 3-year experience in medical writing and edited by medical specialists with relevant clinical and research expertise — all carefully recruited to the team. We strive to enhance patient access to health information, making it expert but easy to understand. All pieces follow the Bookimed’s Editorial Guidelines.
We are made of people and for people — and that"s our core value in Targeted therapy. That"s why all the data presented on the platform is collected, edited, reviewed, and updated regularly by our patients, our partner clinics, and our team, including the Bookimed Medical Advisory Board, which consists of world-renowned doctors with value expertise over 20 years of practice and a positive reputation. Learn more about us and our mission.
In case you find any mistake or have any questions on the information presented on Bookimed.com for Targeted therapy, please feel free to contact us at marketing@bookimed.com.
Dr. Raphael leads Israel's National Genomic Medicine Initiative and pioneers targeted therapy trials at Sourasky Medical Center.
Dr. Pelles Sharon is a respected oncologist with extensive experience in targeted therapy and other advanced cancer treatments at Sourasky Medical Center.
Professor Ofer Merimsky leads the Soft Tissue and Bone Oncology unit at Sourasky Medical Center – Israel's top sarcoma specialist.
Dr. Sarid has published 30+ articles on cancer therapy and leads clinical trials in targeted treatments at Sourasky Medical Center.
Written by Anna Shchur
When considering Targeted therapy, it’s important to understand the different techniques and which is best suited for you. Here’s a concise comparison of popular options:
Lutetium-177 therapy is a targeted radiotherapy utilizing the Lutetium-177 radioisotope to treat certain cancers effectively.
Targeted therapy in Israel uses molecular profiling and genetic testing to identify specific proteins or genes fueling cancer growth. Drugs like monoclonal antibodies or small-molecule inhibitors then block these signals, destroying malignant cells while preserving healthy tissue in JCI-accredited facilities.
Bookimed Expert Insight: Israeli oncology centers often integrate genomic profiling with specialized Tumor Boards to personalize treatment. Data shows centers like Sourasky Medical Center manage 40,000 cancer patients annually, often providing access to proprietary CAR-T therapies for multiple myeloma. This high volume allows doctors like Dr. Ofer Merimsky to refine drug combinations that are often restricted to clinical trials elsewhere.
Patient Consensus: Patients value how these treatments target cell weaknesses while sparing normal tissue. Many note that advanced options like TIL therapy are physically demanding but offer hope when traditional methods fail.
Targeted therapy causes side effects when proteins found on cancer cells are also present on healthy tissue. Common reactions involve the skin, digestive system, and liver. Most symptoms subside within 30 days of treatment completion, though specific agents require ongoing heart and eye monitoring.
Bookimed Expert Insight: While standard targeted therapy in Israel ranges from $9,500 to $19,500, the specific side effect profile often dictates the facility choice. Centers like Sourasky Medical Center (Ichilov) treat over 40,000 cancer patients annually. This high volume means their teams are exceptionally experienced in managing complex infusion reactions and managing strict oral dosing schedules to reduce nausea.
Patient Consensus: Patients often report persistent chills and shaking during certain therapies. They emphasize that adhering to exact fasting windows before taking oral medication is critical for minimizing severe nausea.
Israeli oncology centers use targeted therapy to treat breast, lung, prostate, and gastrointestinal cancers, alongside advanced blood malignancies. Precision oncology programs at facilities like Sourasky Medical Center utilize genomic profiling to identify molecular markers, enabling the use of checkpoint inhibitors, CAR T-cell therapy, and peptide receptor radionuclide therapy.
Bookimed Expert Insight: While many countries import CAR T-cell therapies from the US, Israeli centers like Sheba Medical Center utilize homegrown protocols. This internal development often increases treatment accessibility for complex blood cancers. Patients should ask about clinical trials for TIL therapy if traditional immunotherapy fails for advanced melanoma.
Patient Consensus: Success in Israel often depends on distinguishing between standard targeted drugs and experimental breakthroughs like Alpha DaRT for head and neck cancers. Many emphasize verifying if a treatment is a standard protocol or part of a clinical trial phase.
Targeted therapy is better for patients with tumors showing specific genetic markers, as it selectively attacks cancer cells while sparing healthy tissue. Chemotherapy remains superior for broad application against rapidly dividing cells in cancers lacking identifiable biomarkers like EGFR, ALK, or HER2.
Bookimed Expert Insight: Israeli oncology centers like Sourasky (Ichilov) leverage extensive clinical research to achieve 90% success rates. Specialists such as Dr. Ari Raphael utilize precise genomic-guided protocols that may double survival rates in matched pancreatic cancer cases compared to standard chemotherapy alone. This precision-first model depends on liquid biopsies to monitor tumor evolution and prevent treatment resistance.
Patient Consensus: Patients value how targeted therapy preserves their energy and appearance, though they emphasize that biomarker testing is the essential first step. Many found that personalized protocols provided a practical alternative when traditional chemotherapy was no longer effective.
Targeted therapy in Israel typically lasts between 9 and 18 months on average, though duration varies by cancer stage and medication response. While some patients maintain disease control for 4 or more years, treatment often continues as long as the therapy remains effective.
Bookimed Expert Insight: Israeli oncology centers like Sourasky (Ichilov) leverage Oxford-trained specialists and Joint Commission International (JCI) standards to optimize therapy duration. Data shows that early tumor shrinkage in the first few cycles is a strong predictor of long-term survival. With costs averaging 64% lower than in the US, patients often access advanced genomic profiling like Foundation One CDx to identify resistance markers earlier.
Patient Consensus: Many patients emphasize monitoring early response metrics and testing for specific resistance markers like MET amplification. They often highlight the importance of navigating the emotional shift if resistance develops after the initial months of successful control.